Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

University Hospital, Toulouse400 enrolled

Overview

This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Multiple Sclerosis

Interventions

S1P levelOTHER

Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * French residents enrolled in the social security system * Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not * Patients scheduled for urodynamic assessment as part of their management Exclusion criteria: * Pregnant or lactating females * Patients under legal guardianship * Untreated urinary tract infection at the time of inclusion * Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty

Outcomes

Primary Outcomes

S1P concentration

To compare of the urinary concentration of S1P related to creatinine in urine sample, as a function of the detrusor activity determined at BUD, before and after a first intra-detrusor injection of botulinum toxin.

Time frame: Day 0, after 6 months